Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-26
2010-12-28
Moore, Susanna (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S253120, C514S341000, C514S349000, C544S360000, C546S275400, C546S297000, C546S194000
Reexamination Certificate
active
07858643
ABSTRACT:
Enantiomerically pure compound of formula 1are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
REFERENCES:
patent: 5587458 (1996-12-01), King et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 5877305 (1999-03-01), Huston et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 6071935 (2000-06-01), Lyssikatos
patent: 6080769 (2000-06-01), Lyssikatos et al.
patent: 6106864 (2000-08-01), Dolan et al.
patent: 6150377 (2000-11-01), Lyssikatos et al.
patent: 6194438 (2001-02-01), Yang et al.
patent: 6258824 (2001-07-01), Yang
patent: 6284764 (2001-09-01), Kath et al.
patent: 6465449 (2002-10-01), Kath et al.
patent: 6479513 (2002-11-01), Yang
patent: 6495564 (2002-12-01), Lyssikatos et al.
patent: 6586447 (2003-07-01), Lyssikatos et al.
patent: 6596735 (2003-07-01), Yang
patent: 6682736 (2004-01-01), Hanson et al.
patent: 7230098 (2007-06-01), Cui et al.
patent: 7465842 (2008-12-01), Kung et al.
patent: 7585853 (2009-09-01), Berg et al.
patent: 2003/0166675 (2003-09-01), Yang
patent: 2004/0186113 (2004-09-01), Berg et al.
patent: 2005/0009840 (2005-01-01), Cui et al.
patent: 2005/0227997 (2005-10-01), Noe et al.
patent: 2006/0052396 (2006-03-01), Berg et al.
patent: 2006/0063782 (2006-03-01), Murray et al.
patent: 2006/0128724 (2006-06-01), Cui et al.
patent: 2006/0178374 (2006-08-01), Cui et al.
patent: 2007/0072874 (2007-03-01), Cui et al.
patent: 2008/0293769 (2008-11-01), Cui et al.
patent: 606046 (1994-07-01), None
patent: 780386 (1997-06-01), None
patent: 0 818 442 (1997-07-01), None
patent: 0 952 148 (1999-03-01), None
patent: 1 084 114 (1999-05-01), None
patent: 931788 (1999-07-01), None
patent: 1 004 578 (1999-10-01), None
patent: 9912961.1 (1999-08-01), None
patent: WO 90/05719 (1990-05-01), None
patent: WO 91/11172 (1991-08-01), None
patent: WO 94/02518 (1994-02-01), None
patent: WO 95/19970 (1995-07-01), None
patent: WO 95/21613 (1995-08-01), None
patent: WO 96/27583 (1996-09-01), None
patent: WO 96/33172 (1996-10-01), None
patent: WO 97/13760 (1997-04-01), None
patent: WO 97/22596 (1997-06-01), None
patent: WO 97/32856 (1997-09-01), None
patent: WO 98/02424 (1998-01-01), None
patent: WO 98/02434 (1998-01-01), None
patent: WO 98/02437 (1998-01-01), None
patent: WO 98/02438 (1998-01-01), None
patent: WO 98/03516 (1998-01-01), None
patent: WO 98/07697 (1998-02-01), None
patent: WO 98/14451 (1998-04-01), None
patent: PCT/IB98/01113 (1998-07-01), None
patent: WO 98/30566 (1998-07-01), None
patent: WO 98/33768 (1998-08-01), None
patent: WO 98/34915 (1998-08-01), None
patent: WO 98/34918 (1998-08-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 98/54093 (1998-12-01), None
patent: WO 98/55148 (1998-12-01), None
patent: WO 99/10349 (1999-03-01), None
patent: WO 99/16755 (1999-04-01), None
patent: WO 99/24440 (1999-05-01), None
patent: WO 99/29667 (1999-06-01), None
patent: WO 99/35132 (1999-07-01), None
patent: WO 99/35146 (1999-07-01), None
patent: WO 99/52889 (1999-10-01), None
patent: WO 99/52910 (1999-10-01), None
patent: WO 99/61422 (1999-12-01), None
patent: WO 00/35298 (2000-06-01), None
patent: WO 00/37107 (2000-06-01), None
patent: WO 00/38665 (2000-07-01), None
patent: WO 00/38715 (2000-07-01), None
patent: WO 00/38716 (2000-07-01), None
patent: WO 00/38717 (2000-07-01), None
patent: WO 00/38718 (2000-07-01), None
patent: WO 00/38719 (2000-07-01), None
patent: WO 00/38730 (2000-07-01), None
patent: WO 00/38786 (2000-07-01), None
patent: WO 03/004472 (2003-01-01), None
patent: WO 03/004475 (2003-01-01), None
patent: WO 2004/004720 (2004-01-01), None
patent: WO 2004/055005 (2004-07-01), None
patent: WO2004/076412 (2004-09-01), None
patent: WO 2005/002673 (2005-01-01), None
patent: WO2006/021886 (2006-03-01), None
U.S. Appl. No. 60/168,217 Equiv to WO 01/40217, Nov. 30, 1999, Pfizer Products Inc.
Finnin, B., et al., “Transdermal Penetration Enhancers: Applications, Limitations, and Potential,”Journal of Pharmaceutical Sciences, 1999, 955-958, vol. 88, No. 10.
Haleblian, J., et al., “Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications,”Journal of Pharmaceutical Sciences, 1975, 1269-1288, vol. 64, No. 8.
Jiang, W., et al., “Hypatocyte Growth Factor/Scatter Factor, Its Molecular, Cellular and Clinical Implications in Cancer,”Critical Revues in Oncology Hematology, 1999, 209-248, vol. 29.
Ma, P., et al., “c-MET: Structure, Functions and Potential for Therapeutic Inhibition,”Cancer Metastasis Reviews, 2003, 309-325, vol. 22.
Ma, P., et al., “c-METMutational Analysis in Small Cell Lung Cancer: Juxtamembrane Domain Mutations Regulating Cytoskeletal Functions,”Cancer Research, 2003, 6272-6281, vol. 63.
Maulik, G., et al., “Role of the Hepatocyte Growth Factor Receptor,c-MET, in Oncogenesis and Potential for Therapeutic Inhibition,”Cytokine&Growth Factor Reviews, 2002, 41-59, vol. 13.
Technikova-Dobrova, Z., et al., “Spectrophotometric Determination of Functional Characteristics of Protein Kinases With Coupled Enzymatic Assay,” 1991, FEBS Lett., 69-72, vol. 292, No. 1,2.
Verma, R., et al., “Current Status of Drug Delivery Technologies and Future Directions,”Pharmaceutical Technology On-line, 2001, 1-14, vol. 25, No. 2.
Voller, et al., “Enzyme-Linked Immunosorbent Assay,”Manual of Clinical Immunology 2 Edition, 359-371, Rose And Friedman, Am. Soc. of Microbiology, Washington, D. C., 1980.
Sawyer, T., “Cancer Metastatis Therapeutic Targets and Drug Discovery: Emerging Small-Molecule Protein Kinase Inhibitors,”Expert Opinion on Investigational Drugs, 2004, 1-19, vol. 13, No. 1.
Cui Jingrong Jean
Funk Lee Andrew
Jia Lei
Kung Pei-Pei
Meng Jerry Jialun
Agouron Pharmaceuticals , Inc.
Liptak Vincent P.
Moore Susanna
Prodnuk Stephen D.
Tidwell Jeffrey H.
LandOfFree
Enantiomerically pure aminoheteroaryl compounds as protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enantiomerically pure aminoheteroaryl compounds as protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enantiomerically pure aminoheteroaryl compounds as protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4179386